BioNTech’s predecessor Phase 2 personalized mRNA cancer vaccine program was terminated, underlining execution risk in a crowded personalized oncology vaccine field. The cancellation came just a week after Moderna and Merck posted breakthrough results for a different cancer vaccine pairing. On the operational safety side, separate reporting highlighted pharmacy and provider exposure to cybersecurity threats, including phishing attacks impersonating Epic’s MyChart portal. The guidance emphasizes that increasingly polished scams outpace patients’ ability to detect fakes, shifting responsibility toward provider communication. For biotech and healthcare operators, these stories reinforce two parallel vulnerabilities: clinical program risk in fast-moving modality competitions and growing exposure to digital fraud that can disrupt patient trust and workflows.